Study of of VX-659 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2017
At a glance
- Drugs VX 659 (Primary) ; Ivacaftor; Tezacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions
- 08 Jan 2017 According to a Vertex Pharmacuticals media release, status changed from planning to recruiting.
- 25 Nov 2016 New trial record
- 25 Oct 2016 According to Vertex Pharmaceuticals media release, this study is expected to begin by the end of 2016 .